Skip to Content

Unicycive Therapeutics, Inc.

Securities Class Action

  • Date:
  • 11/2/2026
  • Company Name:
  • Unicycive Therapeutics, Inc.
  • Stock Symbol:
  • UNCY
  • Class Period:
  • FROM 12/29/2025 TO 6/29/2026
  • Status:
  • Filed
  • Filing Date:
  • 9/3/2026
  • Court:
  • U.S. District Court: Northern California

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 2026, both dates inclusive (the “Class Period”). Investors have until November 2, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (1) Unicycive had not inspected its third-party manufacturing vendor’s facility or otherwise audited the facility’s compliance with current good manufacturing practices; (2) as a result, Unicycive lacked a reasonable basis to believe that the vendor had resolved the FDA’s cited deficiencies; (3) there was an undisclosed risk that the FDA would require additional information about the vendor’s facility’s manufacturing practices; (4) as a result of the foregoing, the regulatory approval of oxylanthanum carbonate was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants’ positive statements about Unicycive’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you purchased or otherwise acquired Unicycive shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.

Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions regarding the case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Unicycive Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: